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ABSTRACT
Background    The prion protein (PrP) might be useful 
as a tool to collect cardiac progenitor cells derived from 
embryonic stem (ES) cells. It is also possible that PrP+ 
cells include undifferentiated cells with a capacity to de-
velop into tumors.
Methods    PrP+ cells isolated from embryoid bodies 
(EB) formed by mouse AB1 ES cells were examined us-
ing RT–PCR analysis and clonogeneic cell assay. To as-
sess their potential to differentiate into cardiomyocytes, 
Nkx2.5GFP/+ (hcgp7) cells, another ES cell line that 
carries the GFP reporter gene in the Nkx2.5 loci, were 
used.
Results    PrP+ cells isolated from EB of day 7 and 14 
did not express pluripotency markers, but expressed car-
diac cell markers, while PrP+ cells isolated from EB of 
day 21 expressed pluripotency markers. Cultured PrP+ 
cells isolated from EB of day 21 expressed pluripotency 
markers to form colonies, whereas those isolated from 
EB of day 7 and 14 did not. To exclude proliferating cells 
from PrP+ cells, stage specific embryo antigen 1 (SSEA1) 
was employed as a second marker. PrP+/SSEA1– cells 
did not proliferate and expressed cardiac cell markers, 
while PrP+/SSEA1+ did proliferate.
Conclusion    PrP+ cells isolated from EB included 
undifferentiated cells in day 21. PrP+/SSEA1– cells in-
cluded cardiomyoctes, suggesting PrP and SSEA1 may 
be useful as markers to enrich the fraction of cardiomy-
ocytes.
Key words   cell differentiation; embryonic stem cells; 
prion protein; stage-specific embryonic antigens
Embryonic stem (ES) cells are characterized by their 
capacity for self-renewal and pluripotency. They spon-
taneously differentiate into cardiomyocytes through the 
formation of embryoid bodies (EB).1–4 ES cells-derived 
cardiomyocytes are a potential source for cell-trans-
plantation therapy in patients with a damaged heart.5, 6 
A prerequisite for transplantation of these cells is their 
purity, because undifferentiated ES cells are capable of 
producing tumors.7 A sophisticated method is neces-
sary to isolate cardiac progenitors from among ES cells 
and achieve a fraction of high purity. The normal prion 
protein (PrP) belongs to the glycosylphosphatidyl-ino-
sitol-anchored protein family, and is expressed in adult 
tissues.8–11 The PrP is anchored to the outer surface of 
neurons, lymphocytes and other cells that express Nes-
tin9, 12 and promotes the differentiation of ES cells into 
neuronal progenitor cells.9, 12, 13 The PrP was reported to 
be expressed in the intestine during embryonic develop-
ment9, 14, 15 as well as in the heart and neurons.9, 14–16 The 
PrP was reported to form a complex with stress induced 
phosphoprotein 1 (STIP1) to regulate neuronal develop-
ment.9, 17 The PrP is known to be involved in iron uptake9, 
18 and Ca2+ homeostasis9, 19 and also to play a pivotal role 
in cellular responses against reactive oxygen species 
(ROS) to form superoxide dismutase (SOD) via binding 
to copper.9, 11 Thus, the PrP is essential to responses to 
the environment by cells of the three germ layers. An 
abnormal PrP causes neurodegenerative diseases such 
as Creutzfeldt-Jakob disease, fatal familial insomnia and 
Gerstmann-Sträussler-Scheinker syndrome.10, 11 
 Hidaka et al. reported that the PrP was a marker of 
cardiac progenitor cells in the early phase of EB forma-
tion.16 We also found that most of PrP+ cells differentiat-
ed into cardiomyocytes.20 Since the PrP is expressed in 
various tissues, it is possible that PrP+ cells from ES cells 
include cells different from cardiac progenitor cells. Re-
cently, the PrP was reported to enhance the expression 
of the transcription factor Nanog suggesting that PrP+ 
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cells can proliferate and form tumors after transplanta-
tion.7, 9, 21 This might indicate the harmfulness of PrP+ 
cells as a cell source for transplantation. However, it has 
never been tested whether PrP+ cells from EB include 
undifferentiated cells. In the present study, we attempted 
to characterize PrP+ cells derived from EB formed by 
mouse ES cells. We found that PrP+ cells from EB of 
days 21, but not those of day 7 and 14, expressed plu-
ripotency markers and were capable of proliferation. 
Combining the PrP with stage specific embryo antigen 1 
(SSEA1) as the second marker enabled us to enrich the 
fraction of cardiomyocytes that do not proliferate.
MATERIALS AND METODS
Cell culture and differentiation
AB1 ES cells derived from 129SV/EV mice were kindly 
provided by Dr. Shimotsuke (Riken CDB, Kobe, Japan). 
They were cultured on SNL feeder cells treated with 
mitomycin C (Sigma-Aldrich, St Louis, MO). SNL cells 
were derived from STO mouse embryonic fibroblasts 
with a forced expression of leukemia inhibitory factor 
(LIF) and neomycin resistance genes. AB1 cells were 
grown and maintained in Dulbecco’s-modified Eagle’s 
medium (DMEM; Wako Pure Chemical, Osaka, Japan) 
supplemented with 20% heat-inactivated fetal bovine se-
rum (FBS; Corning, Corning, NY), 1 × penicillin-strep-
tomycin-L-glutamine solution (Wako Pure Chemical), 1 
× MEM non-essential amino acid solution (Wako Pure 
Chemical), 0.1 mM 2-mercaptoethanol (Sigma-Aldrich) 
and 1,000 units/mL LIF (ESGRO; Merck KGaA, Darm-
stadt, Germany). 
 Dr. Morisaki (National Cerebral and Cardiovascular 
Center, Suita, Japan) provided ht7 ES cells. These cells 
carry the hygromycin resistance gene in one of the Oct4 
loci.22 Derived from the ht7 cells, hcgp7 (Nkx2.5GFP/+) 
ES cells carry the GFP reporter gene in one of the 
Nkx2.5 loci.23 Both ht7 and hcgp7 cells were grown and 
maintained on gelatin-coated dishes in Glasgow mini-
mum essential medium (GMEM; Wako Pure Chemical) 
supplemented with 10% heat-inactivated FBS (Corn-
ing), 1 × penicillin-streptomycin-L-glutamine solution 
(Wako Pure Chemical), 1 × MEM non-essential amino 
acid solution (Wako Pure Chemical), 0.1 mM 2-mer-
captoethanol (Sigma-Aldrich), 1 mM sodium pyruvate 
(Wako Pure Chemical), and 1,000 units/mL LIF (Merck 
KGaA), without feeder cells. Differentiation of ES cells 
into cardiac progenitors was induced via formation of 
EB. Briefly, EB were generated by plating 20 µL of cell 
suspension (2.5–10 × 104 cells/mL) in DMEM (Wako 
Pure Chemical) supplemented with 10–20% heat-inacti-
vated FBS (Corning), 1 × penicillin-streptomycin-L-glu-
tamine solution (Wako Pule Chemical), 0.1 mM 2-mer-
captoethanol (Sigma-Aldrich) (EB medium) on the lid 
of a dish, followed by incubation in hanging drops for 2 
days. EB were transferred into the medium and cultured 
as floating EB or attached out-growth cells for indicated 
days until analysis. 
Table 1. Primer list in gene expression analysis
Gene Forward Reverse Annealing temperature No. cycles
Zfp42 TTCACGGAGAGCTCGAAACT CCATCCCCTTCAATAGCTCA 60 30
Nanog CACCCACCCATGCTAGTCTT ACCCTCAAACTCCTGGTCCT 60 28
Oct4 ATTCTCGAACCTGGCTAAGCT ATGGTGGTCTGGCTGAACACCTTT 60 28
Pax6 CAGAAGACTTTAACCAAGGGC TGGGCTATTTTGCTTACAACTT 60 30
NeuroD1 AAGCCATGAATGCAGAGGAGGACT AGCTGCAGGCAGCCGGCGACC 60 30
Afp ACATCAGTGTCTGCTGGCAC AGCGAGTTTCCTTGGCAACAC 60 30
Sox17 AAGAAACCCTAAACACAAACAGCG TTTGTGGGAAGTGGGATCAAGAC 60 30
T GTCTTCTGGTTCTCCGATGT CCAGGTGCTATATATTGCCT 60 30
Mesp1 CAGAATCGTGGGACCCAT CGGCGTCCAGGTTTCTAG 60 30
Tbx5 ATGGTCCGTAACTGGCAAG TTTCGTCTGCTTTCACGATG 60 30
Nkx2.5 ACCGTCGCTACAAGTGCAA CCATAGGCATTGAGACCCA 60 30
Anp TGGGCTTCTTCCTCGTCTT TTCTACCGGCATCTTCTCCT 60 30
Myl7 TGACCCAGGCAGACAAGTTC CGTGGGTGATGATGTAGCAG 60 30
Myl2 AAGGTGTTTGATCCCGAGGG GGGAAAGGCTGCGAACATCT 60 30
Prnp CTGAAGCATTCTGCCTTCCT GCCGACATCAGTCCACATAG 60 30
Gapdh TGAACGGGAAGCTCACTGG TCCACCACCCTGTTGCTGTA 60 25
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Fig. 1. PrP+ cells isolated from EB 
involved the cardiac myocytes.
A: Flow cytometry analysis of cell 
surface PrP in EB derived from 
AB1 ES cells. Ordinate indicates 
the prevalence of DRAQ7-posisitve 
cells as dead cells and abscissa in-
dicated the prevalence of PrP+ cells. 
The cells within a gated area show 
the population of living PrP+ cells.
B: Summary of the fl ow cytometry 
analysis. The graph shows the mean 
and the standard deviation of the 
PrP+ rate in Day 7, 14 and 21 after a 
differentiation induction (n = 3).
C: Prevalence of Nkx2.5/GFP-pos-
itive cell in PrP+ cells isolated from 
EB of hcgp7 at Day 7, 14 and 21. 
The ordinate showed the prevalence 
of PrP+ cells and the abscissa indi-
cated the expression level of Nkx2.5/
GFP-positive cells. The upper panel 
showed the fl ow cytometry analysis 
of ht7 cells, as negative control and 
the lower panel showed the fl ow cy-
tometry analysis on hcgp7 cells.
EB, embryoid body; ES cells, em-
bryonic stem cells; GFP, green fl uo-
rescent protein; PE, phycoerythrin; 
PrP+, prion protein positive.
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Fig. 2. mRNA level of pluripotent, ectodermal, endodermal, me-
sodermal and cardiac cell markers in PrP+ cells from EB at day 
7, 14 and 21. Cells were isolated by FACS, and then mRNA was 
extracted from them. Each set corresponds to the transcript ampli-
fi ed using the indicated primers. (+) : PrP+ cell fraction, (–) : PrP– 
cell fraction. PCR of Gapdh from RNA sample without reverse 
transcriptase [Gapdh RT (–) ] did not show any fragment, indicat-
ing no contamination of cDNA by genomic DNA.
EB, embryoid body; FACS, fluorescence activated cell sorting; 
mRNA, messenger RNA; PrP−, prion protein negative; PrP+, prion 
protein positive; RT, reverse transcription.
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Flow cytometry
Cells were dissociated from EB at day 7 ± 1, 14 ± 1 and 
21 ± 1 by Collagenase type Ⅱ (Worthington, Lakewood, 
NJ) with gentle pipetting, followed by a treatment with 
Cell Dissociation Buffer (enzyme-free, Hanks’-based; 
Thermo Fisher Scientifi c, Waltham, MA) for 5–8 min. 
Cells were stained with phycoerythrin (PE) -conjugated 
anti-PrP (mouse monoclonal clone SAF83; Funakoshi, 
Tokyo, Japan) labeled with the PE Labeling Kit-NH2 
(Dojindo Laboratories, Kumamoto, Japan) according to 
the manufacturer’s instructions. Dead cells were exclud-
ed with Draq7 (Biostatus, Shepshed, England). 
 The percentage of cells positive for PrP or GFP was 
determined by fl ow cytometry (BD FACS Canto II; BD, 
Franklin Lakes, NJ). They were resuspended in Hank’s 
balanced salt solution (HBSS, Wako Pure Chemical) 
containing 2% FBS and Draq7, diluted 100 times, and 
subjected to cell sorting (Mofl o XDP, Beckman Coulter, 
Brea, CA) with Summit software to collect either PrP+ 
or GFP+ cells.20
Clonogenic cell assay
PrP+ cells were isolated from EB at day 7, 14 and 21 
by FACS. 1,000 or 10,000 cells were seeded on gel-
atin-coated dish and cultured in EB medium for 7 to 
17 days. Colonies fixed with 100% ethyl alcohol were 
stained with Giemsa. 
Reverse transcriptase-polymerase chain reaction
Total RNA was isolated from EB using an RNeasy 
Mini Kit (Qiagen, Hilden, Germany), according to the 
manufacturer’s instructions. RNA samples were treated 
with DNaseI (Promega Corporation, Fitchburg, WI) to 
eliminate genomic DNA and cDNA was synthesized 
using the PrimeScript RT reagent Kit with gDNA Eraser 
(Takara Bio, Kusatsu, Japan). PCR amplifi cations were 
performed using Emerald Amp Max polymerase (Takara 
Bio) with primers listed in Table 1.
Statistical analysis
Data are expressed as mean ± SD.
RESULTS
PrP+ cells differentiated into cardiac myocytes
Figure 1A shows representative fl ow cytometry data in-
dicating the prevalence of PrP+ cells in EB of AB1 cells. 
And Fig. 1B shows the summary of the fl ow cytometry 
analysis. The PrP+ rate were 22.9, (s = 5.8. n = 3), 13.7, (s 
= 1.9. n = 3) and 18.3, (s = 12.7. n = 3) (%) in EB of day 
7, 14 and 21, respectively. PrP+ cells were not detected 
in EB before day 4 of differentiation induction (data not 
shown). The prevalence of PrP+ cells expressing Nkx2.5/
GFP was studied using mouse Nkx2.5GFP/+ ES cells. As 
shown in Fig. 1C, the prevalence of PrP+ cells expressing 
Nkx2.5/GFP on days 7, 14 and 21 was 1.3, 0.3 and 0.1%, 
respectively, indicating a decline in the number of cardi-
ac progenitor cells among PrP+ cells.
Heterogeneity of PrP+ cells isolated from EB at 
various periods post differentiation induction
To verify whether PrP+ cells contained undifferentiated 
cells, mRNAs levels of pluripotency markers were ex-
amined in PrP+ cells isolated from EB. Figure 2 shows 
mRNA levels of pluripotency markers (Zfp42, Nanog 
and Oct4), ectoderm cell markers (Pax6, NeuroD1), en-
doderm cell markers (Afp, Sox17), mesoderm cell mark-
ers (T, Mesp1) and cardiac cell markers (Tbx5, Nkx2.5, 
Anp, Myl7 and Myl2) expressed in PrP+ cells isolated 
from EB of days 7, 14 and 21. PrP+ cells from EB of 
day 7 predominantly expressed mRNAs of cardiac cell 
markers. PrP+ cells from EB of day 14 expressed mR-
NAs of ectodermal and endodermal cell markers besides 
mesodermal cell and cardiac cell markers. Surprisingly, 
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Fig. 3. Changes in mRNA level of pluripotent stem, ectodermal, 
endodermal, mesodermal and cardiac cell markers expressed in 
cultured PrP+ cells from EB at various period.
A: PrP+ cells were sorted from EB at day 7 after differentiation 
by FACS and were cultured for another 7 days, and then mRNA 
was extracted from them. Each band corresponds to the transcript 
amplified using the indicated primers.
B: PrP+ cells were sorted from EB at day 14 by FACS and were 
subsequently cultured for another 7 days, and then their mRNA 
was extracted.
C: PrP+ cells were sorted from EB at day 21 by FACS and were 
subsequently cultured for another 7 days, and then their mRNA 
was extracted. AB1 d0: undifferentiated AB1 cells, (+) : PrP+ cell 
fraction, (–) : PrP− cell fraction. PCR of Gapdh from RNA sam-
ple without reverse transcriptase [Gapdh RT (–) ] did not show 
any fragment, indicating no contamination of cDNA by genomic 
DNA.
d, day; EB, embryoid body; FACS, fluorescence activated cell 
sorting; mRNA, messenger RNA; PrP−, prion protein negative; 
PrP+, prion protein positive; RT, reverse transcription.
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Day 7 + 7 Day 14 + 7 Day 21 + 7
PrP−
PrP+
Fig. 4. Proliferation of cultured PrP+ cells derived from EB at day 7, 
14 and 21. 
PrP+ cells were sorted from EB at day 7, 14 and 21 by FACS, and 
were subsequently cultured for 7 days. Each cell was stained by 
Giemsa’s solution. The upper panels: colony formation of PrP− 
cells derived from EB at the various periods. The lower panels: 
colony derived of PrP+ cells derived from EB at the various peri-
ods.
EB, embryoid body; FACS, florescence activated cell sorting; 
PrP−, prion protein negative; PrP+, prion protein positive.
PrP+ cells from EB of day 21 expressed mRNAs of plu-
ripotency markers as well as those of cells of the three 
germ layers.
PrP+ cells from EB included undifferentiated cells 
capable of proliferation
Expression of pluripotency markers suggested the prev-
alence of undifferentiated cells among PrP+ cells from 
EB of day 21. Since undifferentiated cells proliferate in 
a short-term culture, we examined the expression of plu-
ripotency markers in PrP+ cells cultured for 7 days after 
isolation from EB. As shown in Fig. 3A, PrP+ cells from 
EB of day 7 expressed mesodermal, cardiac cell mark-
ers. But, they also expressed pluripotent, ectodermal and 
endodermal cell markers, slightly. PrP+ cells from EB 
of day 14 did not express pluripotency markers, ectoder-
mal or endodermal cell markers after a 7-day culture, 
but they expressed cardiac cell markers in Fig. 3B. PrP+ 
cells from EB of day 21 expressed pluripotency markers 
after a 7-day culture without changes in mRNA levels of 
mesodermal, cardiac, ectodermal and endodermal cell 
markers in Fig. 3C. Next, we examined the capability of 
PrP+ cells from EB to proliferate by means of clonogenic 
cell assay. As shown in Fig. 4, PrP+ cells isolated from 
EB of day 21 formed colonies, while cultured PrP+ cells 
from EB of day 7 and 14 did not. These results indicated 
that PrP+ cells from EB of day 21 contained undifferen-
tiated cells.
Use of PrP and SSEA1 as selection markers to en-
rich the fraction of differentiated cardiomyocytes 
Stage specific embryo antigen 1 (SSEA1) is a surface 
marker of pluripotent stem cells.24 Figure 5A shows 
expression of SSEA1 in PrP+ cells isolated from EB 
of days 7, 14 and 21. The prevalence of PrP+/SSEA1+ 
cells was 0.3%, 0.1% and 0.3%, respectively. Figure 5B 
shows colony formation by PrP+ /SSEA1– cells and PrP+ 
/SSEA1+ cells from EB of day 21 cultured for 10 and 17 
days, respectively. Cultured PrP+ /SSEA1– cells did not 
form any colony, but cultured PrP+ /SSEA1+ cells did, 
indicating SSEA1 is a useful marker to exclude prolif-
erating cells from among PrP+ cells. Figure 5C shows 
cardiac cell markers (Tbx5 and Myl2) expressed in PrP+ 
/SSEA1– cells isolated from EB of day 21. The level of 
mRNA corresponding to cardiac cell markers was com-
parable between PrP+ cells and PrP+ /SSEA1– cells.
DISCUSSION
In the present study, we found that PrP+ cells isolated 
from EB of day 7 and 14 did not express pluripotency 
markers but expressed cardiac cell markers, and that 
PrP+ cells isolated from EB of day 21 expressed pluripo-
tency markers as well as those of the three germ layers; 
that PrP+ cells isolated from EB of day 21 formed colo-
nies and expressed pluripotency markers, whereas those 
from EB of day 7 and 14 did not form colonies; and that 
PrP+/SSEA1– cells expressed cardiac cell markers and 
did not proliferate, while PrP+/SSEA1+ did proliferate.
 Pluripotent stem cells such as ES or induced plu-
ripostent stem cells are a potential cellular source for 
cell transplantation therapy of damaged hearts.16, 20, 25 
However, pluripotent stem cells-derived cells include 
undifferentiated cells. Several groups tried to purify 
cardiomyocytes among differentiated ES cells by mark-
er gene transduction or fluorescence-based purification 
methods. Yet, for clinical use, fast, effective and scalable 
purification methods with no genetic modification are 
essential. A few surface markers that can be used for 
isolation of cardiomyocytes have been reported.16, 23 
Flk1 is a marker of cardiovascular progenitors: common 
progenitors for cardiac, smooth muscle and endothelial 
cells.5 c-Kit is reported to be a cardiovascular stem cell 
marker of adult and embryonic heart.26, 27 Pdgfra is 
widely expressed in the mesoderm, including the cardiac 
lineage.26 Vascular cell adhesion molecule-1 (VCAM-1) 
has been reported as useful to isolate embryonic cardio-
myocytes with 98% purity. VCAM-1 positive cells have 
been reported to specify committed cardiomyocytes,28 
and have been confirmed in human ES cells.29 Recently, 
Hidaka et al. reported the PrP served to predominantly 
enrich the fraction of cardiomyocytes expressing cTnI, 
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Fig. 5. Characterization of PrP+/ SSEA1− cells isolated from EB at various periods. 
A: Prevalence of PrP+/ SSEA1+ cells derived from EB at the various periods. PrP+ cells were sorted from EB at Day 7, 14 and 21 by 
FACS. The ordinate showed the prevalence of PrP+ cells and the abscissa indicated the prevalence of SSEA1+ cells. The upper control 
board showed the fl ow cytometry analysis as negative control and the lower control board showed the fl ow cytometry analysis of PrP+/ 
SSEA1+ cells.
B: Colongenic cell assay of cultured PrP+/ SSEA1− cells from EB at day 21. Either PrP+/ SSEA1+ or PrP+/ SSEA1− cells of 10,000 cells 
were isolated from EB at day 21 by FACS and were subsequently cultured for another 10 and 17 days. Upper panels: colonies of cultured 
PrP+/ SSEA1+ or PrP+/ SSEA1− cells from EB at day 21 for another 10 days stained with Giemsa’s dye. Lower panels: colonies of cultured 
PrP+/ SSEA1+ or PrP+/ SSEA1− cells from EB at day 21 for another 17 days stained with Giemsa’s dye.
C: Enrichment of cardiac myocytes in PrP+/ SSEA1− cells from EB at day 21. PrP− cells, PrP+ cells and PrP+/ SSEA1− cells were sorted 
from EB at day 21 by FACS and were subjected to RT−PCR using indicating primers. PCR of Gapdh from RNA sample without reverse 
transcriptase [Gapdh RT (−) ] did not show any fragment, indicating no contamination of cDNA by genomic DNA.
EB, embryoid body; FACS, fl uorescence activated cell sorting; mRNA, messenger RNA; PE, phycoerythrin; PrP−, prion protein negative; 
PrP+, prion protein positive; RT, reverse transcription, SSEA1−, SSEA1 negative; SSEA1+, SSEA1 positive.
A
133
Markers to enrich cardiomyocyte
and cultured PrP+ cells from EB have been reported to 
differentiate into atrial and ventricular myocytes.16 Hida-
ka et al. also demonstrated that PrP+ cells from EB could 
proliferate, because PrP+ cells included cardiac progeni-
tors.16 Nevertheless, in the present study, PrP+ cells from 
EB of days 21 expressed pluripotency markers and PrP+ 
cells from EB of day 21 proliferated in vitro. In contrast, 
PrP+ cells from EB of day 14 did not express pluripo-
tency markers and did not proliferate. The mechanism 
of re-expression of pluripotency markers in PrP+ cells 
from EB of day 21 remains unclear. The PrP has been 
reported to activate Nanog expression through Integrin 
signaling.9, 25 PrP is known to influence the fate of cells 
and cell cycle besides their pluripotency, suggesting 
that prolonged expression of PrP in cultured cells may 
reactivate pluripotency9, 30 markers leading thereby to 
cell proliferation. Further experiments are necessary to 
examine this possibility. 
 Since individual markers are commonly expressed 
by cells of multiple lineage, a single marker may not 
be sufficient to distinguish cells of the cardiac lineage. 
Combination of two surface markers has been reported 
to be useful for isolation of cells of the cardiac lineage. 
Hidaka et al. used PDGFRa and PrP as markers to im-
prove the purity of the cardiomyocyte fraction.16 The 
present data indicated that PrP+ cells from EB of days 
21 included undifferentiated cells. Thus, for clinical use, 
it is necessary to exclude undifferentiated cells. SSEA1 
is expressed in mouse pluripotent stem cells and is their 
authentic marker. In the present study, PrP+ /SSEA1– 
cells isolated from EB of day 21 included cardiomyo-
cytes but not undifferentiated cells. Taken together, use 
of the PrP with SSEA1 might enable us to enrich the 
fraction of differentiated cardiomyocytes. 
 Clinical implication of the present study might be 
obvious. The transplantation of both c-Kit+ cells isolated 
from the right atrial appendage31 and cardiac progenitor 
cells from endomyocardial biopsies obtained from the 
right ventricular septum32 had been reported to improve 
the cardiac function in patients with ischemic heart dis-
ease, whereas other stem-cell based therapies including 
human bone marrow stem cells or mesenchymal stem 
cells failed to do so.33 This indicated the importance 
of enriching cardiac progenitor cells to exert positive 
effects in the clinical setting. The present provided a 
novel method to collect the cardiac progenitor cells from 
pluripotent stem cells and to exclude the undifferentiat-
ed cells, ensuring the feasibility as well as safety on the 
implantation of the cardiac progenitor cells from plurip-
otent stem cells.
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